TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

280Bio initiates Phase I Clinical Trial for TEB-17231, an Oral Pan-RAS Inhibitor, in Advanced Cancer Patients with KRAS, HRAS, or NRAS Mutations

Saturday, December 02, 2023

280Bio, Inc., a biotechnology company in the clinical stage focused on developing precision oncology medicines, has announced the initiation of treatment for the first patient with TEB-17231 (YL-17231), a small molecule inhibitor designed to target RAS signaling. This compound has demonstrated potent inhibition of tumor cell proliferation in both in vitro and in vivo preclinical studies, showing effectiveness against various KRAS, NRAS, and HRAS alterations, including those resistant to KRAS G12C inhibitors.

As a wholly owned subsidiary of Shanghai Yingli Pharmaceuticals, Inc. (Yingli Pharma) in Shanghai, China, 280Bio is making significant progress in advancing TEB-17231's clinical development. Michael Hui, Chief Executive Officer of 280Bio Inc., expressed satisfaction at reaching this milestone, emphasizing the company's dedication to addressing unmet needs in cancer treatment through precision oncology. He stated, "This marks a major step in TEB-17231's clinical development, and we are eager to provide new therapeutic options for the patients we aim to serve. We anticipate ongoing enrollment and dosing of patients in this trial."

The first patient in the United States was enrolled at The University of Texas MD Anderson Cancer Center in Houston, Texas, under the care of Dr. David Hong, Deputy Chair of Investigational Cancer Therapeutics and the lead investigator for the trial.

Dr. Zusheng Xu, Head of Research and Development at Yingli Pharma, highlighted TEB-17231's broader activity against oncogenic RAS signaling pathways compared to many existing KRAS inhibitors. Recognizing the pressing need for new cancer agents, he expressed hope that TEB-17231 would prove safe and efficacious through continuous oral dosing in patients, reflecting the company's commitment to addressing challenges in cancer treatment through innovative approaches.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit